{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:41:47Z","timestamp":1793788907269,"version":"4.6.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006556","name":"Centre Hospitalier Universitaire de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriatic arthritis (PsA) is associated with increased cardiovascular morbidity and mortality. The aims of our real-life study were to compare the prevalence of cardiovascular risk factors (CVRFs) and cardiovascular events (CVEs) among patients with PsA with a control population, to evaluate the impact of correcting factors in equations that assess cardiovascular risk (CVR) in PsA, and to determine the percentage of patients who reach the LDLc target as indicated by the European guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this observational cross-sectional monocentric case-control study, we used a standardized procedure to systematically assess patients with PsA aged 25\u201385 years who met the Classification for Psoriatic Arthritis (CASPAR) criteria. Controls were extracted from the MOnitoring NAtionaL du rISque Art\u00e9riel (MONALISA) study. We compared the prevalence of CVRFs, CVEs, the CVR, and the percentage of patients reaching recommended LDLc target in both populations. The CVR was first assessed using SCORE and QRISK2 equations. Then, the SCORE equation was corrected by applying a 1.5 multiplication factor, as recommended by EULAR for rheumatoid arthritis (SCORE-PsA), and the QRISK2 was corrected using the \u201crheumatoid arthritis\u201d item (QRISK2-PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 207 PsA and 414 controls were included. CVRFs and CVEs were more frequent in the PsA group. After controlling for age and gender, atherothrombotic disease was increased in the PsA population (SCORE <jats:italic>p<\/jats:italic> = 0.002, QRISK2 <jats:italic>p<\/jats:italic> = 0.001). Using the SCORE-PsA increased the percentage of patients with a high or very high CVR from 39.3 to 45.3% in the PsA group. Similarly, using the QRISK2-PsA increased the percentage of patients with a CVR \u2265 10% from 44.9 to 53.2%. The percentages of patients with PsA with high LDLc in the high and very high CVR groups were not significantly different from controls, despite a trend in favor of patients with PsA. Of the 83 PsA with a QRISK2 \u2265 10%, only 22.9% were treated with statin vs. 35.8% of the 134 controls. The QRISK2-PsA score did not alter these results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In real-life, patients with PsA have a higher prevalence of CVRFs, as well as a higher prevalence of CVEs compared to the general population. The CVR is higher in the PsA population than in the controls either using the SCORE and QRISK2 equations or using the corrected SCORE- PsA and QRISK2-PsA equations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.785719","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:10:56Z","timestamp":1652937056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Yannick","family":"Degbo\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Zabraniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Jamard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Bernard","family":"Ruidavets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ferrieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Ruyssen-Witrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22831","article-title":"The global prevalence of spondyloarthritis: a systematic review and meta-regression analysis.","author":"Stolwijk","year":"2015","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR).","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/ard.2003.018101","article-title":"Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study.","volume":"63","author":"Turesson","year":"2004","journal-title":"Ann Rheumat Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis.","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheumat Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2014-206824","article-title":"On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Tr\u00f8ndelag health study.","volume":"75","author":"Gulati","year":"2016","journal-title":"Ann Rheumat Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","article-title":"Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2013the role of inflammation.","volume":"47","author":"Tam","year":"2008","journal-title":"Rheumatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jbspin.2019.12.004","article-title":"Cardiovascular risk in psoriatic arthritis, a narrative review.","volume":"87","author":"Verhoeven","year":"2020","journal-title":"Joint Bone Spine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"742713","DOI":"10.3389\/fmed.2021.742713","article-title":"Update on cardiovascular risk and obesity in psoriatic arthritis.","volume":"8","author":"Ram\u00edrez","year":"2021","journal-title":"Front Med."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-06002-0","article-title":"Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients.","author":"Galarza-Delgado","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/art.40892","article-title":"A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis.","volume":"71","author":"Kitas","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B12","article-title":"Survival benefit of statin use in ankylosing spondylitis and psoriatic arthritis: a general population-based cohort study [abstract].","author":"Oza","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study.","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.acvd.2009.02.002","article-title":"Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996\u20132007.","volume":"102","author":"Ferri\u00e8res","year":"2009","journal-title":"Arch Cardiovasc Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood institute scientific statement.","volume":"21","author":"Grundy","year":"2006","journal-title":"Curr Opin Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s0195-668x(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update.","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheumat Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review.","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheumat Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/acr.21623","article-title":"Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: results from a French multicenter cohort.","volume":"64","author":"Boyer","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.","volume":"68","author":"Choy","year":"2009","journal-title":"Ann Rheumat Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"B22","author":"Giles","year":"2017","journal-title":"Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial. ACR Meeting Abstracts."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study.","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."},{"key":"B24","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.","volume":"33","author":"Han","year":"2006","journal-title":"J Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.semarthrit.2006.09.001","article-title":"Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis.","volume":"36","author":"Kimhi","year":"2007","journal-title":"Semin Arthritis Rheumat."},{"key":"B26","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/rheumatology\/ken159","article-title":"Hypertension in rheumatoid arthritis.","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease.","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3899\/jrheum.150757","article-title":"Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions.","volume":"43","author":"Haroon","year":"2016","journal-title":"J Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12026-014-8595-z","article-title":"Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.","volume":"61","author":"Costa","year":"2015","journal-title":"Immunol Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jbspin.2013.07.008","article-title":"Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors.","volume":"81","author":"Rosales Alexander","year":"2014","journal-title":"Joint Bone Spine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00296-016-3614-0","article-title":"Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.","volume":"37","author":"Nissen","year":"2017","journal-title":"Rheumatol Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3899\/jrheum.190261","article-title":"Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review.","volume":"47","author":"Colaco","year":"2020","journal-title":"J Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0205506","DOI":"10.1371\/journal.pone.0205506","article-title":"Performances of five risk algorithms in predicting cardiovascular events in patients with psoriatic arthritis: an Italian bicentric study.","volume":"13","author":"Navarini","year":"2018","journal-title":"PLoS One."},{"key":"B34","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10067-019-04442-3","article-title":"Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis.","volume":"38","author":"Navarini","year":"2019","journal-title":"Clin Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1185\/030079905X59139","article-title":"Lipid-modifying therapy and attainment of cholesterol goals in Europe: the return on expenditure achieved for lipid therapy (REALITY) study.","volume":"21","author":"Van Ganse","year":"2005","journal-title":"Curr Med Res Opin."},{"key":"B36","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1136\/annrheumdis-2012-202789","article-title":"Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic.","volume":"72","author":"Rollefstad","year":"2013","journal-title":"Ann Rheum Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.785719\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:11:01Z","timestamp":1652937061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.785719\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":37,"alternative-id":["10.3389\/fmed.2022.785719"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.785719","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"785719"}}